Ashwani Verma
Stock Analyst at UBS
(3.50)
# 1,047
Out of 4,970 analysts
79
Total ratings
53.57%
Success rate
4.88%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $415 → $560 | $400.79 | +39.72% | 7 | Sep 4, 2025 | |
| AVDL Avadel Pharmaceuticals | Maintains: Buy | $13 → $20 | $15.75 | +26.98% | 3 | Aug 21, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $32 → $36 | $25.24 | +42.63% | 5 | Aug 8, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $43 → $38 | $37.90 | +0.28% | 4 | Jul 30, 2025 | |
| IMVT Immunovant | Maintains: Neutral | $17 → $18 | $17.13 | +5.08% | 1 | Jul 28, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $152 → $174 | $144.16 | +20.70% | 9 | Jul 9, 2025 | |
| LEGN Legend Biotech | Maintains: Buy | $60 → $54 | $36.11 | +49.56% | 3 | Jul 2, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $24 → $23 | $18.95 | +21.37% | 9 | Jun 26, 2025 | |
| ALKS Alkermes | Upgrades: Buy | $33 → $42 | $29.95 | +40.23% | 5 | Jun 17, 2025 | |
| INCY Incyte | Maintains: Neutral | $61 | $86.67 | -29.62% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $47 → $41 | $53.07 | -22.74% | 5 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $48 | $35.95 | +33.52% | 2 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $1.30 | -19.23% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $179 | $129.47 | +38.26% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $72.63 | +56.96% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $54 | $15.87 | +240.37% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $107 → $105 | $125.22 | -16.15% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $36.08 | -22.38% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $97.84 | -92.85% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $10.51 | +14.23% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $0.51 | +2,869.12% | 1 | Oct 11, 2022 |
United Therapeutics
Sep 4, 2025
Maintains: Buy
Price Target: $415 → $560
Current: $400.79
Upside: +39.72%
Avadel Pharmaceuticals
Aug 21, 2025
Maintains: Buy
Price Target: $13 → $20
Current: $15.75
Upside: +26.98%
ACADIA Pharmaceuticals
Aug 8, 2025
Maintains: Buy
Price Target: $32 → $36
Current: $25.24
Upside: +42.63%
Exelixis
Jul 30, 2025
Maintains: Neutral
Price Target: $43 → $38
Current: $37.90
Upside: +0.28%
Immunovant
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $17.13
Upside: +5.08%
Neurocrine Biosciences
Jul 9, 2025
Maintains: Buy
Price Target: $152 → $174
Current: $144.16
Upside: +20.70%
Legend Biotech
Jul 2, 2025
Maintains: Buy
Price Target: $60 → $54
Current: $36.11
Upside: +49.56%
Teva Pharmaceutical Industries
Jun 26, 2025
Maintains: Buy
Price Target: $24 → $23
Current: $18.95
Upside: +21.37%
Alkermes
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $29.95
Upside: +40.23%
Incyte
Jun 3, 2025
Maintains: Neutral
Price Target: $61
Current: $86.67
Upside: -29.62%
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $53.07
Upside: -22.74%
Apr 28, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $35.95
Upside: +33.52%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.30
Upside: -19.23%
Mar 7, 2025
Upgrades: Buy
Price Target: $145 → $179
Current: $129.47
Upside: +38.26%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $72.63
Upside: +56.96%
Aug 13, 2024
Maintains: Buy
Price Target: $55 → $54
Current: $15.87
Upside: +240.37%
Aug 6, 2024
Maintains: Buy
Price Target: $107 → $105
Current: $125.22
Upside: -16.15%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $36.08
Upside: -22.38%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $97.84
Upside: -92.85%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $10.51
Upside: +14.23%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $0.51
Upside: +2,869.12%